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Abstract
Background and aim: To analyze the management and outcome of patients with primary 
typical (TC) and atypical lung carcinoids (AC) in Switzerland.
Methods: Retrospective analysis of patients selected from a neuroendocrine tumor (NET) 
registry. Patients were divided into TC and AC according to pathology reports, and 
surgical procedures were grouped as wedge/segmentectomy, lobectomy/bilobectomy 
and pneumectomy. Survival analysis was performed using the Kaplan–Meier method and 
log-rank test.
Results: Over 7 years, 113 pulmonary carcinoids (61.9% females, mean age 59.4 years) 
were included from 19 hospitals, with pathology data on Ki67 and necrosis incomplete 
in 16 cases. Eighty-three TC and 14 AC underwent surgical resection with a primary 
tumor size of median 14.5 (range 1–80) mm and diagnosis was established in 55.8% at 
surgery. Mean follow-up was 30.2 ± 23.1 months. Lobectomy was performed in 54.2% 
and wedge resection in 17.7% of cases. Six patients received additional systemic therapy. 
There was a trend for larger primary lesion size and a significantly higher rate of N2–N3 
status in AC. Mean survival tended to be increased in patients with TC compared to AC 
(86.1 vs 48.4 months, P = 0.06) and mean disease-free interval after surgical resection was 
74.1 and 48.3 months for TC and AC, respectively (P = 0.74).
Conclusion: AC of the lung has a more malignant behavior and a trend to a worse 
outcome. The results of this registry reinforce the need for standardized histological 
diagnosis and inter-disciplinary therapeutic decision making to improve the quality of 
care of patients with TC and AC.
Introduction
Neuroendocrine tumors of the lungs (LNET) represent 
approximately 30% of all NET (1, 2) and account for 1–2% 
of all lung tumors. Lung NETs are classified into typical 
carcinoid (TC, low-grade tumors) and atypical carcinoid 
(AC), which are considered intermediate-grade tumors. 
Small-cell lung cancer and large-cell neuroendocrine 
carcinoma of the lung are considered high-grade neoplasms 
according to the WHO 2015 classification (3), with poor 
prognosis. Rindi and coworkers (4) have proposed a new 
prognostic classification based on mitotic count and 
presence of necrosis as the WHO adding Ki67 labeling 
index, but this is not universally accepted. Separation of TC 
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from AC requires a surgical specimen, as TC and AC cannot 
be reliably distinguished from each other in small biopsies 
or cytology due to sampling bias and is determined by the 
presence or absence of necrosis and increased mitotic count. 
Compared to TC of the lung, AC has a worse prognosis, 
more frequently metastasizes locally to hilar lymph nodes, 
and also distally to other organs (5).
Regarding the management of pulmonary carcinoids, 
Caplin and coworkers (6) have published a recent European 
Neuroendocrine Tumor Society expert consensus with 
recommendations for best practice: Patients are staged 
according to the UICC 7th TNM classification and surgery 
is the recommended therapy of choice in localized 
disease. Techniques are lobectomy or sleeve resection, 
with a complete anatomic resection and systematic nodal 
dissection recommended in patients with peripheral 
tumors. Lymphadenectomy and its extent are still 
debated but are recommended using the European Society 
of Thoracic Surgeons (ESTS) guidelines (7). Locoregional 
options include surgery (for primary and metastases) and 
endobronchial therapies, but trans-catheter embolization 
and radiofrequency therapy have been proposed for 
slowly progressive LNET. Following complete resection, 
the options are limited, as adjuvant chemotherapy or 
radiation therapy are not standard of care.
SwissNET is a prospective ongoing nationwide registry 
of patients with NET of all organs. Its goal is to collect data 
from NET cases in order to provide quality assessments, 
to advance knowledge and to establish standard of care 
for NET. Ultimately, this will enable to improve care and 
reduce the morbidity and mortality of patients with NET 
in Switzerland. The primary aim of the current study was 
to analyze the management and outcome of patients with 
TC and AC of the lung in Switzerland. The secondary aims 
included (i) the analysis of clinical and biomedical factors 
associated with surgical therapy and survival and (ii) the 
analysis of the current treatment strategies in Switzerland 
in relation to current guidelines.
Subjects and methods
SwissNET registry
Since 2009, clinical data on Swiss patients with NETs 
have been documented in a nationwide prospective 
database, the SwissNET registry (http://www.swissnet.
net/). Currently, 45 participating hospitals across all of 
Switzerland are providing voluntarily SwissNET with 
data on their patients with NET. Data are collected by 
professional research nurses directly from the pathologists 
and treating physicians at the respective hospitals or 
medical doctors report the diagnosis of NET to SwissNET 
directly. The patients are then contacted and written 
informed consent is obtained, in which the patients agree 
to the use of pseudonymised data for research purposes. 
In case of non-consent, the data are not registered.
The inclusion criteria for the SwissNET registry 
comprise all patients with well-differentiated NET of 
the aero-digestive tract irrespective of age, based on the 
revised WHO criteria 2010 (8). Patients with small-cell 
and large-cell neuroendocrine carcinomas of the lung 
are excluded from the analysis. All NETs, irrespective of 
sporadic or familial origin, are included. Follow-up is 
performed yearly by research nurses collecting the data at 
the respective hospitals.
Study design and population
For the current analysis, all patients diagnosed with TC and 
AC from the SwissNET registry were selected, from February 
2009 to March 2016, with data acquired from 5 university 
hospitals and 14 community hospitals. The Ethics Review 
Board of the University Hospitals of Geneva approved this 
particular study (2016-00506), based on the multi-centric 
Ethics Review Board approval for the nationwide registry 
in Switzerland (395/14; NCT01039922).
Data from the registry were available for this study 
in coded form. Pathological grading was performed 
according to the WHO 2010 classification (8). 
Immunohistochemical analysis with chromogranin, 
synaptophysin and CD56 was documented to confirm 
neuroendocrine differentiation. In addition, Ki67 index 
and presence or absence of necrosis was recorded.
Patients and surgical outcomes were staged according 
to the UICC 7th TNM classification (9). Surgical procedures 
were recorded and grouped as wedge, segmentectomy, 
lobectomy and bilobectomy versus pneumectomy. The 
respective teams in each center decided the need and 
timing for additional chemo- or radiation therapy based 
on age, comorbidities, carcinoid syndrome, resection 
status and/or extent of disease.
Statistical analysis
Descriptive analyses were performed to determine the 
prevalence and current therapy modalities. Continuous 
data are presented as mean ± standard deviation (s.d.) or 
median (range) and were analyzed using a two-tailed t test 
and the Mann–Whitney U test, as appropriate. A two-sided 
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P value <0.05 was considered statistically significant. 
Follow-up time was determined from the date of diagnosis 
to the date of death or last follow-up for survivors. Disease-
free interval (DFI) represents the time in months following 
R0 resection, with no evidence of local recurrence or distant 
metastasis on imaging. Survival analyses using the Kaplan–
Meier method were performed to determine outcomes, 
and log-rank test was performed for comparison. Statistical 
analyses were performed using SPSS, version 21 (IBM).
Results
Patient characteristics and diagnostics
Of 1050 patients with NET in the registry, 113 were 
classified as well-differentiated LNET and represent 
the study cohort. Patient demographics and clinical 
characteristics are shown in Table  1. The mean age at 
diagnosis was 59.4 ± 12.9 years, with 70 (61.9%) patients 
being female. The tumors were incidentally found in 
19 (16.8%) cases and overall 18 (15.9%) patients had 
functioning tumors (one case presented with Cushing’s 
syndrome and the others had TC syndrome), with an 
additional patient with multiple endocrine neoplasia type 
1 (MEN1). The mean interval between symptoms and 
diagnosis was 6 ± 9.9 months. Overall, the follow-up time 
was 30.2 ± 23.1 months, ranging from 1 to 88 months, and 
leading to a median of 4 (1–16) visits per patient. Sixteen 
patients were lost to follow-up.
Imaging data at diagnosis were available in 108 of the 
113 patients, showing that for axial imaging, 8 (7.4%) had 
a chest X-ray first, followed by 83 (73.5%) with a CT scan 
and 2 (1.9%) had additional abdominal MRI. Looking at 
functional imaging, 6 (5.3%) underwent somatostatin 
receptor scintigraphy, 5 (4.4%) 68Gallium-DOTA-PET/CT 
and 26 (23.0%) patients underwent FDG-PET for oncological 
workup at diagnosis. Additionally, 1 patient underwent 
bone scintigraphy. Those studies resulted in the diagnosis 
of primary lesions in 72 (66.7%) of the 108 patients who 
underwent imaging studies. Furthermore, in 3 patients, 
lymph-nodes were suspected, and 3 patients were diagnosed 
with liver and 3 with bone metastases at diagnosis.
As for laboratory workup, data in the registry were 
incomplete. In 20 patients, median Chromogranin A was 
60.8 (20–1773) µg/L, for a normal upper limit of 85 µg/L. 
In 9 patients, mean Neuron Specific Enolase (NSE) was 
16.6 ± 6.1 µg/L, for a normal upper limit of 13 µg/L. 
Laboratory values for 5-HIAA, Gastrin, Insulin, Glucagon 
and Serotonin were available in less than 4 patients.
Surgery and pathological staging
Overall, 63.7% of the cohort was treated in 5 University 
centers and 36.3% in 14 community hospitals. Of the 
113 patients in the cohort, first diagnosis was established 
in 9 (8%) patients on cytology and in 41 (36.2%) with 
biopsy, however in 63 (55.8%) patients the diagnosis 
was established by surgical resection. As shown in 
Table 1, surgical resections in 96 patients were classified 
as: Wedge resection in 17 (17.7%), segmentectomy in 9 
(9.4%), lobectomy in 52 (54.2), bilobectomy in 3 (3.1%), 
pneumectomy in 2 (2.1%) and bronchial resection in 2 
(2.1%) patients. In 11 (11.5%) cases, the resection was 
classified as a general lung surgery procedure. Overall this 
resulted in a R0 primary tumor resection in 94.9% of cases.
Analyzing TNM pathological findings, primary 
tumor size was a median of 14.5 (1–80) mm. In 69 
(61.1%) of the patients the information on surgical 
lymph-node sampling was available and in 4 (5.7%) of 
these cases no intraoperative sampling was performed. 
This resulted in N0 for 50 cases, N1 in 9, N2 in 5 and 
Table 1 Patient demographics and clinical characteristics 
(N = 113).
Variable Value
Age at diagnosis (years, mean ± s.d.) 59.4 ± 12.9
Sex (female, n (%)) 70 (61.9)
Functioning (yes, n (%))
Carcinoid/Cushing
MEN1
18 (15.9)
16 (14.2)/1 (0.9)
1 (0.9)
Tumors incidentally found (yes, n (%)) 19 (16.8)
Follow-up time (months, mean ± s.d.) 30.2 ± 23.1 (1–88)
Center type (n (%))  
 University/General Hospital 72 (63.7)/41 (36.3)
Surgical resectiona (n (%))  
 Wedge
 Segmentectomy
 Lobectomy
 Bilobectomy
 Pneumectomy
 Bronchial resection
 Lung Surgery (undefined)
17 (17.7)
9 (9.4)
52 (54.2)
3 (3.1)
2 (2.1)
2 (2.1)
11 (11.5)
Result primary tumor resectionb (n (%))  
 R0 resection 94 (94.9)
Size of primary lesion (mm, median 
(range))
14.5 (1–80)
Ki67 (%, median (range)) 2 (0–80)
Histological typec (n (%))  
 Typical/atypical 83 (73.5)/14 (12.4)
Necrosisd (no/yes, n (%)) 41 (36.3)/2 (1.8)
Values are mean ± s.d. for continuous and n (%) for categorical variables.
a17 cases with missing surgical information, N = 96; b14 cases with missing 
outcome information, N = 99; c16 cases with missing histology 
information, N = 97; d70 cases with missing information on the presence 
or absence of necrosis, N = 43.
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N3 in 1 case. As for distant metastases, 27 were M0 and 
2 were M1.
At histology, a cohort of 113 patients was labeled 
well-differentiated NET and details on Ki-67 labeling was 
available in 80 (70.8%) patients, with a median Ki67 of 
2 (0–35)%. As for histological description of necrosis in 
the registry reports (present/absent), it was available in 
only 38.1% (43/113) of cases, with 41 (36.3%) without, 
and 2 (1.8%) with necrosis. Thus, based on the pathology 
reports in the registry, the overall cohort was classified 
into 83 (73.5%) TC cases and 14 (12.4%) AC cases, with 
information for classification missing in 16 cases. When 
comparing pathological data between TC and AC, results 
show an expected significant difference in Grade and Ki67 
index, with higher values for AC, as shown in Table 2. 
There is a trend for a larger size of primary lesion in AC 
and a significant higher rate of N2-N3 status in AC cases. 
AC presented with significantly higher staging than TC.
Additional medical therapy
Overall, 6 patients in the cohort underwent chemotherapy 
and/or radiotherapy during their disease course. Two 
patients had metastatic disease at diagnosis and received 
octreotide LAR treatment every 28  days at 30 mg. 
One of them underwent sequentially a combination 
of carboplatin and etoposide therapy, external beam 
radiation and as alternative treatment modality 
two cycles of peptide receptor radionuclide therapy 
(PRRT; 177-Lutetium-DOTATOC) with stable disease 
at last follow-up. The other patient underwent first a 
combination chemotherapy with cisplatin and etoposide, 
followed by external radiation, with complete remission 
at last follow-up. Three recurred within 6  months of 
local treatment represented by a R0 resection, presenting 
liver and bone metastases. They all three underwent a 
combination chemotherapy of carboplatin and etoposide; 
one had radiofrequency ablation (RFA) to the liver and 
one had additional external radiation (66 gy). One of 
them is in complete remission at the last follow-up, 
the two others progressed while on therapy. The last 
patient received systemic therapy after undergoing R1 
resection in the presence of bone metastases. This patient 
progressed while on carboplatin and etoposide therapy 
and underwent additional treatments in form of RFA and 
external radiation.
Table 2 Comparison between TC and atypical carcinoid (N = 97a).
Variable TC AC P value
Grade, n (%)    
 G1
 G2
77 (92.8)
6 (7.2)
2 (14.3)
12 (85.7)
<0.0001*
Ki 67, in %, mean ± s.d. 4.05 ± 11.8 9.22 ± 9.99 <0.0001§
Tumor size, in mm, mean ± s.d. 18.6 ± 14.8 36.2 ± 26.1 0.053§
Type of resectionb, n (%)    
 Wedge
 Segmentectomy
 Lobectomy
14 (23.0)
7 (11.5)
40 (65.6)
0 (0)
1 (14.3)
6 (85.7%)
0.36#
Lymphadenectomyc, n (%)    
 Yes
 No
29 (87.9)
4 (12.1)
7 (100)
0 (0)
0.45#
Nodal statusd s.d., n (%)    
 N0
 N1
 N2–N3
39 (81.3)
7 (14.6)
2 (4.2)
6 (60)
0
4 (40)
0.008#
Staged, n (%)    
 IA
 IB
 IIA
 IIB
 IIIA
 IIIB
33 (67.4)
6 (12.2)
7 (14.3)
0
2 (4.1)
1 (2.0)
3 (33.3)
2 (22.3)
0
1 (11.1)
3 (33.3)
0
0.009# 
 
 
 
 
Groups were compared using the Pearson Chi-square test* (or Fisher’s exact test#) for categorical variables and the Wilcoxon Mann–Whitney test§ for 
continuous variables; values are mean (s.d.) for continuous and n (%) for categorical variables.
aCohort in this table represents the 97 patients who could be classified into TC and AC based on pathological criteria (16 missing data from total 113 WD 
LungNET); b96 cases underwent surgery, with 18 cases either surgical or pathology missing information, N = 78; c57 cases with missing intraoperative 
information on lymphadenectomy, N = 40; d39 cases with missing staging information, N = 58.
AC, atypical carcinoid; n, number of patients in cohort; s.d., standard deviation; TC, typical carcinoid.
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Survival analysis
Overall, analysis shows that the mean survival for 
TC tended to be longer, at 86.1  months compared to 
48.4  months for AC, P = 0.069 (Fig.  1). The mean DFI 
was 73.9  months for the entire cohort, with TC at a 
mean DFI of 74.1 (range 66.8–81.5) months and 48.3 
(range 26.8–69.9) months for AC, P = 0.745 (Fig.  2). 
Looking at outcome, there was no difference in DFI 
with regards to the type of surgical resection, P = 0.98, 
and a trend toward slightly better outcome was noted 
comparing lobar resection (mean DFI 72.4 months) to 
Figure 1
Kaplan–Meier survival distribution in months for 
the bronchial carcinoid classification. Cohort 
includes the 97 patients classified into TC and AC. 
Follow-up time was determined from the date of 
diagnosis to the date of death or last follow-up 
for survivors. Patients lost to follow-up and with 
unknown status (16 cases) were excluded.
Figure 2
Kaplan–Meier disease-free interval estimates in 
months for the bronchial carcinoid classification. 
Cohort includes the 97 patients classified into TC 
and AC who had R0 resection. Patients lost to 
follow-up and with unknown status at last 
follow-up were excluded. Disease-free interval 
(DFI) represents the time in months following R0 
resection, with no evidence of local recurrence or 
distant metastasis on imaging.
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sub-lobar resection (wedge or segmentectomy) (mean 
DFI 65.2 months). Of note, the number of patients was 
small in the different subgroups, as well as the numbers 
of events for DFI: 2 deaths, 2 relapses and 2 progressions. 
Furthermore, there was no difference in survival or DFI 
stratified for lymph-node status (log-rank test P = 0.31, 
data not shown).
Discussion
The main findings of this study can be summarized as 
follows: (1) the workup, management and follow-up 
for pulmonary carcinoids were highly variable between 
centers and more than half of the cases were diagnosed at 
surgical resection; (2) patients with AC had larger primary 
lesions and a significantly higher rate of positive lymph-
nodes and higher grading than TC.
For a long time, bronchial carcinoids were considered 
rare lesions with benign behavior, characterized by a better 
prognosis than other primary malignancies of the lung. 
Nowadays, they are considered malignant tumors because 
of their potential to locally invade, to develop lymph-
node and distant metastases and to recur. This behavior 
is accounted for especially by AC (10, 11, 12, 13), shown 
in a recent study stratifying TC vs AC with statistically 
significant survival difference and thus confirming the 
validity of the WHO classification used in the present 
study (4). The more aggressive behavior of AC compared 
to TC documented in the present data, corroborates 
with other published studies. Like others, the results 
show that AC are characterized with a greater tendency 
to develop lymph-node metastases and have a higher 
recurrence rate (11, 14). The present study did not show a 
significant difference for lymph-node status (N0 vs N+) in 
terms of overall survival and DFI, suggesting nodal status 
might have a lower impact on survival of patients with 
bronchial carcinoids, despite the fact that AC had a higher 
rate of positive lymph-nodes. This might be due to small 
sample size and to the short follow-up time in this study. 
This finding differs from literature reports, such as the 
study by Cardillo and coworkers (14) showing that nodal 
status had more influence on prognosis than histological 
subtype. However, Garcia-Yuste and coworkers (15) have 
demonstrated in a multi-centric study that the atypical 
subtype was at high risk of recurrence, aligned with our 
results.
Regarding the type of recommended surgical 
resection, lobectomy with lymph-node sampling was 
the most frequently performed procedure in our cohort. 
However, no significant difference in DFI was found 
with regards to the type of surgical resection, when 
comparing lobar resection to sub-lobar resection (wedge 
or segmentectomy). These results are to be taken with 
caution, as the term ‘sub-lobar’ includes both wedge 
resections and segmentectomies, with wedge resections 
representing oncologically incomplete resections and 
segmentectomies considered anatomical and oncological 
resections. In literature, Filosso and coworkers (11) found 
anatomical resections to be a protective factor against 
distant metastases, stating that wedge resections in 
their opinion are inappropriate for this type of tumors, 
even in the case of TC. However, a recent SEER database 
report suggested no difference in survival in univariate 
or multivariate analysis when comparing sub-lobar to 
lobectomy or greater surgeries (10), even when controlling 
for age and stage, thus corroborating our study’s data. 
Other studies showed an increased rate in loco-regional 
recurrence in patients with AC undergoing sub-lobar 
resections, but found no significant difference in overall 
survival (16, 17). Furthermore, anatomical localization of 
lesions (central vs peripheral) might dictate the extent of 
resection needed, information that was not available in 
this registry. Therefore, prospective, randomized multi-
centric studies are required to better understand the 
role of lung-sparing surgeries versus anatomical lobar or 
bronchial resections.
The European Neuroendocrine Tumor Society recently 
published an expert consensus and recommendations for 
best practice regarding the management of typical and 
atypical pulmonary carcinoids in 2015 (6). They state 
that pathology is the gold standard in the assessment 
of any pulmonary NET diagnosis, with problem cases 
benefiting from review by expert pathologists. They insist 
these pathology reports be shared by multidisciplinary 
teams along with oncologists, surgeons, radiologists, 
nuclear medicine physicians, pneumologists and 
endocrinologists, where pathologists contribute to the 
clinical decision-making process. All these specialists 
should have experience in treating NETs. In our study, 
description and reporting of pathology was highly 
variable and incomplete; however, the data were collected 
since 2009. Labeling with Ki-67 was not available in all 
patients (only in 71%), the classification into TC or AC 
was missing in 16 cases and as for histological description 
of necrosis in the reports, it was available in only 38.1% of 
cases. In our opinion, standardized pathological reporting 
is of utmost importance for the management of these 
patients, as outcome of disease and management differ 
between these two subgroups. Such reporting should 
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be requested by the multidisciplinary teams taking 
decisions for therapy. Furthermore, Caplin and coworkers 
recommend that patients be staged according to the UICC 
7th TNM classification and that somatostatin scintigraphy 
SPECT/CT is useful to determine the N and M stage in 
the preoperative phase, especially in well-differentiated 
carcinoids; FDG-PET/CT might be useful in intermediate 
or poorly differentiated tumors. Additionally, whenever 
available, 68Gallium-DOTA-PET should be preferentially 
performed, as it is more sensitive than scintigraphy 
when investigating possible metastases. In our study, 
less than 33% of the cohort had functional imaging at 
diagnosis, with only 5 patients undergoing 68Gallium-
DOTA-PET. The ‘under’-utilization of functional images 
in this study might be due to the fact that in most 
cases, the diagnosis of TC or AC was made after surgical 
resection and/or because of the unawareness of the 
‘lung’ NET community about the utility of these imaging 
modalities and lastly, because receptor-based imaging 
is currently not reimbursed in Switzerland. According 
to the consensus, surgery is the recommended therapy 
of choice for localized disease. Standard techniques 
are anatomical resections (segmentectomy, lobectomy, 
sleeve resection, pneumonectomy), with nodal dissection 
recommended in all patients. Also, lung-sparing surgery 
is preferred over pneumonectomy whenever possible. In 
our cohort, lymphadenectomy was performed in most 
AC cases, but the information was missing in more than 
1/3 of the cohort, suggesting that the lymph-node status 
was not adequately evaluated in most of these patients. 
Lymphadenectomy and its extent is still debated but are 
recommended according to the ESTS guidelines and a 
recent European practice survey (18).
In further consensus recommendations, SSA may 
be considered as first-line systemic anti-proliferative 
treatment for patients with advanced unresectable 
LNET with loco-regional options including surgery (for 
primary and metastases), trans-catheter embolization 
or radiofrequency therapy. Chemotherapy has been 
the standard for aggressive metastatic LNET and PRRT 
is an option in patients with tumors that demonstrate 
strong expression of somatostatin receptors; however, 
the observed frequent use of cisplatin in Switzerland is 
not backed-up by clinical trials and might reflect the 
standard chemotherapy used by pulmonary oncologists. 
Additional systemic treatment was performed in 6 
patients of the studied cohort, making analyses and 
recommendations based on our study impossible. Very 
recent evidence suggests that everolimus has a beneficial 
effect on progression-free survival in patients with lung 
carcinoids (19). This therapeutic option was not reported 
in the SwissNET registry, probably due to the only recent 
approval and incompleteness of data. Finally, the general 
recommendation after primary surgery is that patients 
with TC and AC should be followed long-term.
Our study has limitations that are intrinsic to every 
registry. Essentially the data are observational and may, 
therefore, be prone to selection bias. Furthermore, due to 
the retrospective design of this study, diverse treatment 
strategies and non-standardized pathological analyses 
were reported, with essential data missing. In Switzerland, 
a new law on cancer registration will make reporting 
mandatory starting in 2019. Finally, the follow-up time of 
patients with lung carcinoids was short in order to draw 
firm conclusion. Thus, the results have to be interpreted 
with caution.
In conclusion, the quality of care of patients 
with TC and AC in Switzerland can be improved and 
standardized with regards to histological diagnosis, 
clinical decisions regarding imaging, surgery and medical 
treatments. Furthermore, the recent advances made in 
treatments of gastro-entero-pancreatic NET were not 
frequently applied to LNET, and overall, management 
was highly variable between centers with pathological 
and surgical information incomplete, either because 
of lack of standardized protocols or under-reporting. 
Thus, even though SwissNET is now an established and 
well-functioning registry, the quality of data reporting/
collection could be improved and most importantly, 
multidisciplinary decision-making in the management of 
patients with TC and AC should be more standardized in 
Switzerland.
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